What is IGC Pharma, Inc. (IGC)?

IGC Pharma, Inc. (IGC) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of IGC?

The current price of IGC is $0.24. Prices are updated in real time on Stocks360.

What is IGC's price-to-earnings (PE) ratio?

IGC's trailing twelve-month PE ratio is -2.90, based on current price and earnings per share data available on Stocks360.

What is IGC's market capitalization?

IGC's market capitalization is $24,677,763.00, placing it in the small-cap tier.

IGC Pharma, Inc. (IGC)

Stock analysis · AMEX · Healthcare · Biotechnology

$0.24

Market Cap

$24.68M

PE (TTM)

-2.90

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.48

Day Range

$0.24 – $0.25

52-wk Range

$0.24 – $0.45

Avg Volume

N/A

Volume

509.51K

IGC Pharma, Inc. (IGC) is a publicly traded company in the Healthcare sector. Latest price: $0.24. Market cap $24.68M. Trailing PE -2.90. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $0.40 2026-10-28 · $0.24 (-40.95%)

Earnings

Most Recent

Aug 14, 2026

EPS $-0.03 vs est. $-0.02

Missed by $0.01

Next Earnings

Nov 13, 2026

EPS estimate $-0.02

Proprietary Signals

Signal snapshot temporarily unavailable.

About IGC Pharma, Inc.

IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-2.90×
P/S (TTM)	21.97×
P/B	3.91×
PEG	0.30×
P/FCF (TTM)	-4.04×
EV / EBITDA	-3.42×
EV / Sales	22.64×
Earnings Yield	-32.92%
Free Cash Flow Yield	-24.73%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$25.43M
Revenue (TTM)	$1.12M
Net Income (TTM)	-$8.12M
Free Cash Flow (TTM)	-$6.67M
Net Debt	$751.00K
Working Capital	-$1.95M
Gross Margin	21.91%
Operating Margin	-986.82%
Net Margin	-702.14%
Return on Equity	-113.58%
Return on Invested Capital	-153.62%